AFP-L3% (Alpha-Fetoprotein-L3 Percent) is a specialized blood test that measures the percentage of a specific subtype of alpha-fetoprotein (AFP) in the bloodstream. AFP is a protein normally produced by the liver and yolk sac during fetal development. In adults, elevated AFP levels can be a sign of liver disease or cancer, particularly hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
AFP exists in different forms, and AFP-L3 is a glycosylated variant that is more specifically associated with malignant liver tumors. The AFP-L3% refers to the proportion of total AFP that is the L3 subtype, offering more precise insight into the risk or presence of liver cancer.
Why is AFP-L3% tested?
This marker is most commonly used in conjunction with total AFP levels to:
-
Aid in early detection of hepatocellular carcinoma (HCC)
-
Distinguish between benign liver conditions and malignant tumors
-
Monitor high-risk patients, such as those with chronic hepatitis B or C, or cirrhosis
-
Assess cancer progression or recurrence in individuals previously diagnosed with liver cancer
How is AFP-L3% interpreted?
-
Low or undetectable AFP-L3%: Generally suggests a lower risk of liver cancer, especially when total AFP is normal.
-
Elevated AFP-L3% (typically >10%): May indicate a higher risk or presence of hepatocellular carcinoma, even if total AFP is not markedly elevated. A rising AFP-L3% over time can be an early sign of cancer development.
Important: AFP-L3% should not be used as a standalone diagnostic tool. It is most effective when interpreted alongside imaging studies (like liver ultrasound or MRI), total AFP levels, and clinical history.
Who should get tested?
AFP-L3% is typically recommended for:
-
Individuals with chronic liver disease (especially hepatitis B or C)
-
People with cirrhosis
-
Those being monitored for liver cancer recurrence after treatment
-
Individuals with elevated total AFP but inconclusive imaging results
In summary:
AFP-L3%, Serum is a highly specific biomarker used to help detect and monitor liver cancer risk, especially in people with existing liver conditions. When combined with total AFP and imaging, it provides a more accurate picture of liver health and helps guide further diagnostic or treatment decisions.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.